Edesa Biotech, Inc. (EDSA) — SEC Filings
Edesa Biotech, Inc. (EDSA) — 24 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 10 8-K, 6 10-Q, 2 DEF 14A.
View Edesa Biotech, Inc. on SEC EDGAR
Overview
Edesa Biotech, Inc. (EDSA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Edesa Biotech, Inc. filed an 8-K on December 12, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Stellar Biotechnologies, Inc., with a name change effective January 20, 2012.
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 1 bearish, 22 neutral, 1 mixed. The dominant filing sentiment for Edesa Biotech, Inc. is neutral.
Filing Type Overview
Edesa Biotech, Inc. (EDSA) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 1 10-K, 2 SC 13D/A, 1 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of EDSA's 20 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
Key Executives
- Dr. Pardeep Nijhawan
- Carlo Sistilli
- Patrick Marshall
- Dr. Parimal Sadhu
- Dr. Michael R. Bristow
- Dr. Michael J. Ybarra
Industry Context
Edesa Biotech operates in the highly competitive pharmaceutical preparations sector, specifically focusing on clinical-stage drug development. The industry is characterized by long development cycles, high R&D costs, significant regulatory oversight, and the potential for substantial returns upon successful drug commercialization. Companies in this space often rely on external financing to fund their operations until they achieve profitability.
Top Tags
biotech (5) · 10-Q (4) · financials (4) · amendment (4) · financial-reporting (2) · material-agreement (2) · corporate-update (2) · filing (2) · corporate-governance (2) · pharmaceutical (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | for the three and nine months ended June 30, 2025, indicating no commercial products |
| Outstanding balance on revolving credit facility | $1,000,000 | as of October 31, 2023, from Pardeep Nijhawan Medicine Professional Corporation |
| Date of Series A-1 Preferred Stock issuance | October 30, 2024 | to Dr. Pardeep Nijhawan |
| Date of Series B-1 Preferred Stock issuance | February 12, 2025 | to various beneficial owners |
| SEC File Number | 001-37619 | Commission file number for Edesa Biotech, Inc. |
| Net Loss | -2,261,334 | Six months ended March 31, 2024 |
| Loss per Share | 0.05 | Six months ended March 31, 2024 |
| Total Assets | 1,776,005 | As of March 31, 2024 |
| Total Debt | 0 | As of March 31, 2024 |
| Directors to be elected | 7 | Election of directors |
| Additional shares | 67,000 | Amendment to 2019 Equity Incentive Plan |
| Meeting Date | May 30, 2024 | 2024 Annual General and Special Meeting |
| Record Date | April 2, 2024 | Shareholders eligible to vote |
Forward-Looking Statements
- {"claim":"Edesa Biotech will continue to report net losses in the near term due to ongoing R&D expenses and lack of revenue.","entity":"Edesa Biotech, Inc.","targetDate":"2024-09-30","confidence":"high"}
- {"claim":"The company will likely need to secure additional financing to fund its operations and drug development programs.","entity":"Edesa Biotech, Inc.","targetDate":"2025-02-09","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Edesa Biotech, Inc. (EDSA)?
Edesa Biotech, Inc. has 24 recent SEC filings from Jan 2024 to Dec 2025, including 10 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EDSA filings?
Across 24 filings, the sentiment breakdown is: 1 bearish, 22 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Edesa Biotech, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Edesa Biotech, Inc. (EDSA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Edesa Biotech, Inc.?
Key financial highlights from Edesa Biotech, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EDSA?
The investment thesis for EDSA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Edesa Biotech, Inc.?
Key executives identified across Edesa Biotech, Inc.'s filings include Dr. Pardeep Nijhawan, Carlo Sistilli, Patrick Marshall, Dr. Parimal Sadhu, Dr. Michael R. Bristow and 1 others.
What are the main risk factors for Edesa Biotech, Inc. stock?
Of EDSA's 20 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Edesa Biotech, Inc.?
Recent forward-looking statements from Edesa Biotech, Inc. include guidance on {"claim":"Edesa Biotech will continue to report net losses in the near term due to ongoing R&D expenses and lack of reve and 1 other predictions.